Saphnelo approved in Japan for systemic lupus erythematosus
28 September 2021 07:00 BST Saphnelo approved in Japan for systemic lupus erythematosus Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus AstraZeneca's Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus (SLE), a serious autoimmune disease, who show insufficient response to currently available treatment. The approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) was based on efficacy and safety